CytomX Therapeutics CTMX Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's accounts receivable?
- CytomX Therapeutics (CTMX) reported accounts receivable of $646K in Q1 2026.
- How has CytomX Therapeutics's accounts receivable changed year-over-year?
- CytomX Therapeutics's accounts receivable decreased by 67.0% year-over-year, from $1.96M to $646K.
- What is the long-term trend for CytomX Therapeutics's accounts receivable?
- Over 5 years (2020 to 2025), CytomX Therapeutics's accounts receivable has grown at a 20.3% compound annual growth rate (CAGR), from $798K to $2.01M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.